Related references
Note: Only part of the references are listed.Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
Mette Deleuran et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)
A. Wollenberg et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Atopic Dermatitis in Older Adults: A Review of Treatment Options
Ryoji Tanei
DRUGS & AGING (2020)
Efficacy of biologics in atopic dermatitis
Jianni Wu et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Pharmacological management of atopic dermatitis in the elderly
Alexander N. Howell et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis
Emma Guttman-Yassky et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Conjunctivitis in dupilumab clinical trials
B. Akinlade et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Keeping an eye on the ocular problems in dupilumab clinical trials
Chia-Yu Chu
BRITISH JOURNAL OF DERMATOLOGY (2019)
Aging and the Immune System: the Impact of Immunosenescence on Viral Infection, Immunity and Vaccine Immunogenicity
Soo-Jin Oh et al.
IMMUNE NETWORK (2019)
Validation of the peak pruritus numerical rating scale: Results from clinical studies of dupilumab in adult patients with moderate-to-severe atopic dermatitis
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Atopic dermatitis in older adults: A viewpoint from geriatric dermatology
Ryoji Tanei et al.
GERIATRICS & GERONTOLOGY INTERNATIONAL (2016)
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
E. L. Simpson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Normal ageing is associated with an increase in Th2 cells, MCP-1 (CCL1) and RANTES (CCL5), with differences in sCD40L and PDGF-AA between sexes
A. S. Mansfield et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2012)
The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
JM Hanifin et al.
EXPERIMENTAL DERMATOLOGY (2001)
Share Paper
